Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 4
2011 3
2012 8
2013 20
2014 13
2015 6
2016 5
2017 7
2018 14
2019 11
2020 6
2021 13
2022 9
2023 4
2024 7
2025 14
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Results by year

Filters applied: . Clear all
Page 1
Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis.
Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y. Atluri DK, et al. Neurogastroenterol Motil. 2014 Apr;26(4):499-509. doi: 10.1111/nmo.12292. Epub 2013 Dec 18. Neurogastroenterol Motil. 2014. PMID: 24351035
BACKGROUND: Treatment options for constipation-predominant irritable bowel syndrome (IBS-C) are limited. While linaclotide improved IBS-C symptoms in randomized controlled trials (RCTs), results vary among studies and the magnitude of ben …
BACKGROUND: Treatment options for constipation-predominant irritable bowel syndrome (IBS-C) are limited. While linac …
Recent advances in the treatment of irritable bowel syndrome.
Bonetto S, Fagoonee S, Battaglia E, Grassini M, Saracco GM, Pellicano R. Bonetto S, et al. Pol Arch Intern Med. 2021 Aug 30;131(7-8):709-715. doi: 10.20452/pamw.16067. Epub 2021 Aug 30. Pol Arch Intern Med. 2021. PMID: 34463082 Free article. Review.
It affects about 20% of the general population, mainly women, and has a considerable impact on the quality of life and health care costs. Four different entities of IBS have been identified: IBS with constipation (IBS- C), IBS with diarrh …
It affects about 20% of the general population, mainly women, and has a considerable impact on the quality of life and health care costs. Fo …
Linaclotide for constipation-predominant IBS.
[No authors listed] [No authors listed] Drug Ther Bull. 2013 Nov;51(11):129-32. doi: 10.1136/dtb.2013.11.0218. Drug Ther Bull. 2013. PMID: 24227771
Irritable bowel syndrome is a chronic relapsing disorder characterised by abdominal pain or discomfort associated with defaecation, abdominal bloating and a change in bowel habit. IBS may be classified by the change in bowel function as 'diarrhoea predominant' (IBS- …
Irritable bowel syndrome is a chronic relapsing disorder characterised by abdominal pain or discomfort associated with defaecation, abdomina …
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.
Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. Chang L, et al. Gastroenterology. 2022 Jul;163(1):118-136. doi: 10.1053/j.gastro.2022.04.016. Gastroenterology. 2022. PMID: 35738724
This American Gastroenterological Association guideline is intended to support practitioners in decisions about the use of medications for the pharmacological management of IBS-C and is an update of a prior technical review and guideline. METHODS: The Grading of Rec …
This American Gastroenterological Association guideline is intended to support practitioners in decisions about the use of medications for t …
The gut microbiota participates in the effect of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C): a multicenter, prospective, pre-post study.
Zhou J, Wei H, Zhou A, Xiao X, Xie X, Tang B, Lin H, Tang L, Meng R, Yuan X, Zhang J, Huang C, Huang B, Liao X, Zhong T, He S, Gu S, Yang S. Zhou J, et al. J Transl Med. 2024 Jan 23;22(1):98. doi: 10.1186/s12967-024-04898-1. J Transl Med. 2024. PMID: 38263117 Free PMC article.
BACKGROUND: Interindividual variation characterizes the relief experienced by constipation-predominant irritable bowel syndrome (IBS-C) patients following linaclotide treatment. ...METHODS: IBS-C patients were administered a daily lina …
BACKGROUND: Interindividual variation characterizes the relief experienced by constipation-predominant irritable bowel syndrome (I …
Linaclotide.
Kalola UK, Patel P, Chowdhury YS. Kalola UK, et al. 2024 Feb 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. 2024 Feb 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 35201736 Free Books & Documents.
Linaclotide is an FDA-approved medication indicated for adults suffering from irritable bowel syndrome with predominant constipation (IBS-C) and chronic idiopathic constipation (CIC). Linaclotide, administered daily, is a potent and highl …
Linaclotide is an FDA-approved medication indicated for adults suffering from irritable bowel syndrome with predominant constipati …
Linaclotide: promising IBS-C efficacy in an era of provisional study endpoints.
Sayuk GS. Sayuk GS. Am J Gastroenterol. 2012 Nov;107(11):1726-9. doi: 10.1038/ajg.2012.325. Am J Gastroenterol. 2012. PMID: 23160292 Free PMC article.
Recent disappointing developments in the pharmacotherapy of irritable bowel syndrome (IBS) have not dampened the enthusiasm surrounding linaclotide, a novel guanylate cyclase-C agonist for the management of constipation-predominant IBS (IBS …
Recent disappointing developments in the pharmacotherapy of irritable bowel syndrome (IBS) have not dampened the enthusiasm surroundi …
Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociación Mexicana de Gastroenterología, 2024.
Remes-Troche JM, Coss-Adame E, Schmulson M, García-Zermeño KR, Amieva-Balmori M, Carmona-Sánchez R, Gómez-Escudero O, Gómez-Castaños PC, Icaza-Chávez ME, López-Colombo A, Morel-Cerda EC, Valdovinos-Díaz MÁ, Valdovinos-García LR, Villar-Chávez AS. Remes-Troche JM, et al. Rev Gastroenterol Mex (Engl Ed). 2025 Jan-Mar;90(1):77-110. doi: 10.1016/j.rgmxen.2024.10.009. Epub 2025 Apr 29. Rev Gastroenterol Mex (Engl Ed). 2025. PMID: 40307155 Free article. Review.
Antispasmodics (alone or combined) are used as first-line therapy for pain management, whereas antidiarrheals, such as loperamide, are used for reducing diarrhea in diarrhea-predominant IBS (IBS-D) and laxatives are used for constipation in constipation …
Antispasmodics (alone or combined) are used as first-line therapy for pain management, whereas antidiarrheals, such as loperamide, are used …
Efficacy and safety of linaclotide in treatment-resistant chronic constipation: A multicenter, open-label study.
Yoshihara T, Kessoku T, Takatsu T, Misawa N, Ashikari K, Fuyuki A, Ohkubo H, Higurashi T, Iwaki M, Kurihashi T, Nakatogawa M, Yamamoto K, Terada I, Tanaka Y, Morita M, Nakajima A. Yoshihara T, et al. Neurogastroenterol Motil. 2024 Dec;36(12):e14938. doi: 10.1111/nmo.14938. Epub 2024 Oct 6. Neurogastroenterol Motil. 2024. PMID: 39370607 Clinical Trial.
BACKGROUND: This study aimed to evaluate the efficacy and safety of linaclotide in patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C) who did not respond to treatment with magnesium oxide (MgO). METHODS …
BACKGROUND: This study aimed to evaluate the efficacy and safety of linaclotide in patients with chronic constipation (CC) or …
Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial.
Peng LH, Fang JY, Dai N, Shen XZ, Yang YL, Sun J, Yang YS. Peng LH, et al. J Dig Dis. 2022 Feb;23(2):99-110. doi: 10.1111/1751-2980.13081. J Dig Dis. 2022. PMID: 35019221 Free PMC article. Clinical Trial.
OBJECTIVE: To conduct a sub-cohort analysis to evaluate the efficacy and safety of linaclotide in Chinese patients with constipation-predominant irritable bowel syndrome (IBS-C) using data from a completed trial (NCT01880424). METHODS: In this phase II …
OBJECTIVE: To conduct a sub-cohort analysis to evaluate the efficacy and safety of linaclotide in Chinese patients with constipati …
138 results